ReviewCurrent opinion in neurobiology2020
Gut-brain communication in demyelinating disorders.
Review in Current opinion in neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Plasma and Visceral Organ Kynurenine Metabolites Correlate in the Multiple Sclerosis Cuprizone Animal Model.International journal of molecular sciences · 2025Article
- Intestinal mucosal alterations parallel central demyelination and remyelination: insights into the gut-brain axis in the cuprizone model of multiple sclerosis.Frontiers in immunology · 2025Article
- Opioid Use and Gut Dysbiosis in Cancer Pain Patients.International journal of molecular sciences · 2024Review
- A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis.Scientific reports · 2024Article
- Remyelination in multiple sclerosis, along with its immunology and association with gut dysbiosis, lifestyle, and environmental factors.Annals of medicine and surgery (2012) · 2023Review
- Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.Brain : a journal of neurology · 2022Article
- Oligodendrocyte progenitors as environmental biosensors.Seminars in cell & developmental biology · 2021Review
- Contributions of neuroimmune and gut-brain signaling to vulnerability of developing substance use disorders.Neuropharmacology · 2021Review
- The Contribution of Gut Microbiota-Brain Axis in the Development of Brain Disorders.Frontiers in neuroscience · 2021Review
- The role of gut-immune-brain signaling in substance use disorders.International review of neurobiology · 2021Article
- The Brain-gut Axis-where are we now and how can we Modulate these Connections?Current neuropharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Multiple Sclerosis (MS) is an autoimmune demyelinating disorder resulting from the interplay of genetic predisposition and environmental variables, including gut microbiota, diet and life style factors. Here, we first discuss the evidence supporting the effect of early life events, diet and body mass index on the composition of the microbiota, and then review studies on gut dysbiosis conducted in MS patients and in animal models. We address the effect of disease, immunomodulatory therapies, diet and probiotics on enrichment or depletion of gut microbial species. Finally, we discuss the ability of gut bacteria to produce toxins and metabolites which serve as signals for the cross-talk between the gut and the brain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.